Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

By A. Bamias, E. Kastritis, C. Bamia, L. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou and 2 more. Journal of Clinical Oncology, 2005

1,186 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d3a931f27a50f57a04e4899f2fa27b0eba7362cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. S. Khosla
2. R. Dansey
3. Nelson B. Watts

In Orthopedics and Sports Medicine

1. S. Khosla
2. L. Raisz
3. R. Dansey
4. Nelson B. Watts

Citations in the corpus

• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research (2007, background): “However, for those who received zoledronic acid alone, the hazard was 1% within the first year but rose to 21% at 3 yr.((18))”
• Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws (2006, background): “In contrast, it was 0% in the first year and 4% in the third year for patients receiving pamidronate alone or with subsequent zoledronic acid (32).”
• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. (2012, background): “Studies suggest that the risk of ONJ may increase with the potency of the antiresorptive agent and duration of treatment [1, 3, 5, 14, 15, 18, 20].”
• Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, neutral): “115,116 Whether concomitant chemotherapy or glucocorticoid use leads to an increased risk of ONJ is unknown.”